Tioconazole

證據等級: L5

預測適應症: 3 個

Tioconazole: From Vaginal Candidiasis to Vulvovaginitis

One-Sentence Summary

Tioconazole is a topical imidazole antifungal whose established clinical use, based on decades of published literature, is the treatment of vaginal (vulvovaginal) candidiasis and other superficial mycoses. The TxGNN model predicts it may also be effective for Vulvovaginitis (a broader diagnostic category encompassing candidal, trichomonal, and mixed vaginal infections), with 2 clinical trials and 20 publications currently supporting this direction.

Quick Overview

Item	Content
Original Indication	Not specified in structured regulatory data (drug is not currently marketed in this jurisdiction); per literature, established use is topical treatment of vaginal candidiasis / superficial mycoses
Predicted New Indication	Vulvovaginitis
TxGNN Prediction Score	99.23%
Evidence Level	L2
US Market Status	Not Marketed
Number of NDAs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available from DrugBank. Based on the literature evidence provided, tioconazole is a substituted imidazole antifungal agent that inhibits fungal ergosterol biosynthesis, giving it broad-spectrum activity against dermatophytes, yeasts (notably Candida albicans), and even some trichomonads and Gram-positive bacteria.

Vulvovaginitis is a broad clinical diagnosis that frequently overlaps with vaginal candidiasis, trichomonal vaginitis, bacterial vaginosis, and mixed infections — the exact indications for which tioconazole already has decades of published clinical support. The TxGNN prediction is therefore less a discovery of a novel mechanism and more a confirmation that tioconazole’s known antifungal/antimicrobial activity extends to the broader “vulvovaginitis” diagnostic umbrella, as demonstrated by multiple RCTs comparing tioconazole to placebo, econazole, clotrimazole, and oral ketoconazole across mixed vaginal infection populations.

Because the drug’s core pharmacology (topical, local antifungal action with some antitrichomonal/antibacterial activity) is well matched to the polymicrobial nature of vulvovaginitis, the mechanistic plausibility is high even without formal MOA documentation.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT03839875	Phase 4	Completed	116	Open-label, single-arm study of Gynomax® XL Ovule (tioconazole-based) evaluating efficacy/safety in trichomonal vaginitis, bacterial vaginosis, candidal vulvovaginitis, and mixed vaginal infections
NCT06056947	Phase 3	Completed	577	Randomized 3-arm study comparing new fenticonazole+tinidazole+lidocaine formulations against Gynomax® XL Ovule (tioconazole) across bacterial vaginosis, candidal vulvovaginitis, trichomonal vaginitis, and mixed infections

Literature Evidence

PMID	Year	Type	Journal	Key Findings
6347833	1983	RCT	Gynäkologische Rundschau	Double-blind comparison of tioconazole vs placebo confirming efficacy, tolerance, and low systemic absorption in vaginal candidiasis
6347834	1983	RCT	Gynäkologische Rundschau	3-day tioconazole vs econazole showed comparable efficacy and tolerability in vaginal candidiasis
6873744	1983	RCT	Gynäkologische Rundschau	3-day tioconazole cream vs econazole ovules showed comparable efficacy and safety
3524439	1986	RCT	Antimicrob Agents Chemother	Single-dose 6.5% tioconazole ointment vs 3-day clotrimazole: 84% vs 85% asymptomatic at 4-week follow-up
6094282	1984	RCT	J Int Med Res	Single-dose topical tioconazole 6% vs 5-day oral ketoconazole: comparable eradication rate, faster symptom relief with topical route
3510114	1986	Review	Drugs	Broad review confirming antimicrobial spectrum and established efficacy/safety of tioconazole in vaginal candidiasis and superficial mycoses
40464716	2025	Review	Expert Rev Anti Infect Ther	Recent review of non-invasive azole treatment options for vulvovaginal candidiasis, situating tioconazole among current azole therapies
10470518	1999	Review	Compr Ther	Review of epidemiology, diagnosis, and therapy of vulvovaginitis in otherwise healthy women
4025721	1985	Cohort	Ala J Med Sci	Clinical and cytological assessment supporting efficacy of tioconazole in vulvovaginal candidiasis
3984688	1985	Cohort	Acta Obstet Gynecol Scand	Tioconazole 2% vaginal cream (3-day regimen) achieved an 88.5% mycological cure rate in symptomatic vaginal candidiasis

US Market Information

Tioconazole currently has no approved product licenses on record in this jurisdiction (total_licenses = 0), consistent with its “Not Marketed” status.

Safety Considerations

Please refer to the package insert for safety information.

(Note: label-derived warnings, contraindications, and drug-interaction data were not retrievable at this time — this is a blocking gap for formal safety assessment; see Conclusion.)

Conclusion and Next Steps

Decision: Hold

Rationale: Efficacy evidence for the vulvovaginitis indication is reasonably strong for a repurposing candidate (Evidence Level L2 — one completed Phase 3 RCT plus multiple supporting older RCTs and reviews), and the drug’s known antifungal/antimicrobial activity is mechanistically well matched to this diagnostic category. However, a blocking data gap — absence of TFDA-equivalent label warnings and contraindications — prevents the candidate from entering the initial safety screening stage (S1), and the drug is currently not marketed in this jurisdiction (0 licenses).

To proceed, the following is needed:

Official product label / warnings & contraindications (to unblock S1 safety screening)
Confirmed mechanism of action from DrugBank (currently unavailable)
Confirmation of available/required dosage forms and routes for the vulvovaginitis indication
Drug-drug interaction data, if the product is intended for markets where it will be co-prescribed
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.